Sage Therapeutics, Inc. (SAGE) Position Increased by Teachers Advisors LLC
Teachers Advisors LLC boosted its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 10.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 130,677 shares of the biopharmaceutical company’s stock after purchasing an additional 12,605 shares during the quarter. Teachers Advisors LLC owned about 0.35% of Sage Therapeutics worth $10,407,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 138 shares in the last quarter. Turner Investments LLC purchased a new position in Sage Therapeutics in the second quarter worth about $159,000. Dubuque Bank & Trust Co. purchased a new position in Sage Therapeutics in the second quarter worth about $167,000. Canada Pension Plan Investment Board purchased a new position in Sage Therapeutics in the second quarter worth about $175,000. Finally, Ameritas Investment Partners Inc. purchased a new position in Sage Therapeutics in the first quarter worth about $180,000.
Sage Therapeutics, Inc. (NASDAQ:SAGE) opened at 63.31 on Tuesday. The stock’s 50 day moving average price is $75.08 and its 200 day moving average price is $74.55. Sage Therapeutics, Inc. has a 12-month low of $38.30 and a 12-month high of $90.80. The company’s market capitalization is $2.37 billion.
Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same period last year, the business earned ($1.08) earnings per share. On average, equities analysts anticipate that Sage Therapeutics, Inc. will post ($7.37) EPS for the current fiscal year.
Several research analysts have recently issued reports on SAGE shares. Canaccord Genuity dropped their target price on shares of Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a research note on Tuesday, September 12th. Leerink Swann reissued an “outperform” rating and set a $97.00 price target (up previously from $90.00) on shares of Sage Therapeutics in a research report on Tuesday, June 20th. SunTrust Banks, Inc. restated a “buy” rating and issued a $82.00 price objective (down from $95.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. Stifel Nicolaus began coverage on shares of Sage Therapeutics in a report on Wednesday, August 9th. They issued a “buy” rating and a $104.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Sage Therapeutics in a research report on Tuesday, June 13th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $86.77.
Sage Therapeutics Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.